NEW YORK (GenomeWeb) – Atlanta-based Cocrystal Pharma today announced licensing agreements with Duke University and Emory University for CRISPR/Cas9 technologies to be used in developing and commercializing antiviral therapeutics for hepatitis B virus (HBV) and human papilloma virus (HPV).

"We are excited to explore the CRISPR/Cas technologies to potentially develop the first virus-targeted genome-modifying treatment that may be able to provide a cure for HPV and HBV," Cocrystal CEO Jeffrey Meckler said in a statement.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

Researchers find that a personalized medicine approach could help people who experience pain while taking statins, New Scientist reports.

US National Science Foundation is continuing its responsible research conduct training policy despite its flaws, ScienceInsider reports.

A CRISPR-themed meeting explored how the tool could and should be used, Wired reports.

In Science this week: database of proteins' effects on cancer, targeted error correction sequencing, and more.

Sep
12
Sponsored by
PerkinElmer

This webinar will cover recent advances in the use of CRISPR for generating animal models and cell lines.